201
|
Inoue M, Sasazuki S, Wakai K, Suzuki T, Matsuo K, Shimazu T, Tsuji I, Tanaka K, Mizoue T, Nagata C, Tamakoshi A, Sawada N, Tsugane S. Green tea consumption and gastric cancer in Japanese: a pooled analysis of six cohort studies. Gut 2009; 58:1323-32. [PMID: 19505880 DOI: 10.1136/gut.2008.166710] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Previous experimental studies have suggested many possible anti-cancer mechanisms for green tea, but epidemiological evidence for the effect of green tea consumption on gastric cancer risk is conflicting. OBJECTIVE To examine the association between green tea consumption and gastric cancer. METHODS We analysed original data from six cohort studies that measured green tea consumption using validated questionnaires at baseline. Hazard ratios (HRs) in the individual studies were calculated, with adjustment for a common set of variables, and combined using a random-effects model. RESULTS During 2 285 968 person-years of follow-up for a total of 219 080 subjects, 3577 cases of gastric cancer were identified. Compared with those drinking <1 cup/day, no significant risk reduction for gastric cancer was observed with increased green tea consumption in men, even in stratified analyses by smoking status and subsite. In women, however, a significantly decreased risk was observed for those with consumption of > or =5 cups/day (multivariate-adjusted pooled HR = 0.79, 95% confidence interval (CI) = 0.65 to 0.96). This decrease was also significant for the distal subsite (HR = 0.70, 95% CI = 0.50 to 0.96). In contrast, a lack of association for proximal gastric cancer was consistently seen in both men and women. CONCLUSIONS Green tea may decrease the risk of distal gastric cancer in women.
Collapse
Affiliation(s)
- M Inoue
- Epidemiology and Prevention Division, Research Center for Cancer Prevention and Screening, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
202
|
Kumamoto T, Takeda K, Ishibe A, Morioka D, Matsuo K, Tanaka K, Endo I, Sekido H, Togo S, Shimada H. Complete neurological recovery from fulminant hepatic failure with subarachnoid hemorrhage by living donor liver transplantation: a case report. Transplant Proc 2009; 41:1982-6. [PMID: 19545774 DOI: 10.1016/j.transproceed.2009.01.108] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2008] [Revised: 08/07/2008] [Accepted: 01/08/2009] [Indexed: 11/25/2022]
Abstract
A 29-year-old man was referred to our hospital with fulminant hepatic failure (FHF) and stage III hepatic coma (somnolence and confusion). Living donor liver transplantation (LDLT) was planned for 2 days after admission to our hospital. However, on the day after admission, he lapsed into stage IV hepatic coma: no right reflexes and no response to pain stimuli. Emergency cranial computed tomography revealed a subarachnoid hemorrhage (SAH), but no aneurysm was seen on magnetic resonance angiography. We speculated that the cause of the SAH may have been bleeding of intracranial veins secondary to coagulopathy and overextension of a vein due to brain edema. We considered that only LDLT could improve the coagulopathy and brain edema. The patient recovered consciousness on postoperative day (POD) 2 and was finally discharged from the hospital without neurological deficit on POD 85. This case suggested that SAH is not a prohibiting factor for LDLT in an FHF patient if the cause of the SAH is venous bleeding.
Collapse
Affiliation(s)
- T Kumamoto
- Department of Gastroenterological Surgery, Yokohama City University Graduated School of Medicine, Yokohama, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
203
|
Haba H, Tsukada K, Asai M, Toyoshima A, Ishii Y, Toume H, Sato T, Nishinaka I, Ichikawa T, Ichikawa S, Nagame Y, Sato W, Matsuo K, Kitamoto Y, Tashiro Y, Shinohara A, Saito J, Ito M, Ikezawa T, Sakamaki M, Goto S, Kudo H, Kikunaga H, Arai M, Kamataki S, Yokoyama A, Akiyama K, Sueki K, Oura Y, Schädel M, Brüchle W, Kratz JV. Extraction behavior of rutherfordium into tributylphosphate from hydrochloric acid. RADIOCHIM ACTA 2009. [DOI: 10.1524/ract.2007.95.1.1] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
The extraction behavior of rutherfordium (Rf) into tributylphosphate (TBP) from hydrochloric acid (HCl) has been studied together with those of the lighter group-4 elements Zr and Hf. The extractability of261Rf,169Hf, and85Zr into TBP was investigated under identical conditions in 7.2–8.0 M HCl by on-line reversed-phase extraction chromatography. The percent extractions of Rf, Hf, and Zr into the TBP resin increase steeply with increasing HCl concentration, and the order of extraction is Zr > Hf ≈ Rf. By considering the order of chloride complexation among these elements, it is suggested that the stability of the TBP complex of Rf tetrachloride is lower than those of Zr and Hf.
Collapse
|
204
|
Okasaka T, Matsuo K, Hosono S, Kawase T, Tanaka H, Yokoi K, Tajima K. 3502 HOGG1 Ser326Cys polymorphism plays a role in lung cancer susceptibility: Analyses stratified by histologic type and smoking status. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)70690-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
205
|
Nakai T, Bagarinao E, Miyakoshi M, Chen A, Tseng I, Matsuo K. Augmented Activation in Aging Brain Depends on the Context of Motor Execution. Neuroimage 2009. [DOI: 10.1016/s1053-8119(09)71532-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
206
|
Nakane T, Nakai T, Miyakoshi M, Naganawa S, Matsuo K, Chen SHA. Comparison of the Hippocampal Activation between Concrete and Abstract Pictures – A preliminary Evaluation for Clinical fMRI. Neuroimage 2009. [DOI: 10.1016/s1053-8119(09)71773-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
207
|
Matsuo K, Huang JSE, Wu CY, Tseng WYI, Chen SHA. Differential Activation in the Hippocampus Among Three Adult Age Groups. Neuroimage 2009. [DOI: 10.1016/s1053-8119(09)71142-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
208
|
Agarwal S, Alonso A, Soliman E, Chamberlain A, Ambrose M, Simpson R, Heiss G, Senga M, Fujii E, Dohi K, Sugiura S, Yamazato S, Nakamura M, Ito M, Bulkova V, Fiala M, Wichterle D, Chovancik J, Simek J, Havranek S, Brada J, Ivanova K, Kawamiya T, Kato K, Fujimaki T, Tanaka S, Yajima K, Hibino T, Yokoi K, Murohara T, Sprenger C, Oeff M, Haeusler KG, Tebbe U, Breithardt G, Meinertz T, Ravens U, Steinbeck G, Cozma DC, Pescariu S, Petrescu L, Luca C, Stoica L, Golda F, Morar M, Dragulescu SI, Ahmed S, Ranchor AV, Rienstra M, Wiesfeld ACP, Van Veldhuisen DJ, Van Gelder IC, Smit MD, Lefrandt JD, Van Gelder IC, Cozma DC, Pescariu S, Luca C, Petrescu L, Dragulescu SI, Inoue K, Makita N, Matsuo K, Shiono Y, Matsuo A, Fujita H, Kitamura M, Inoue K, Makita N, Matsuo K, Shiono Y, Matsuo A, Fujita H, Kitamura M, Providencia RA, Botelho A, Quintal N, Silva J, Seca L, Gomes PL, Leita-Marques AM, Ozcan Celebi O, Canbay A, Celebi S, Sahin D, Aydogdu S, Diker E, Bolohan FR, Leustean M, Indries V, Mihai M, Alexandru R, Cristian G, Ionescu DD, Zysko D, Gajek J, Kucharski W, Mazurek W, Atea LF, Arenal A, Datino T, Gonzalez-Torrecilla E, Atienza F, Calvo D, Almendral J, Fernandez-Aviles F, Chudzik M, Cygankiewicz I, Klimczak A, Oszczygiel A, Wranicz JK, Shaheen M, Patel D, Sonne K, Venkatraman P, Armanijian L, Bailey SM, Burkhardt JD, Natale A, Tunyan LG, Grigoryan SV, Gashi M, Pllana EP, Kocinaj DK, Hoyo J, Benito L, Fornes B, Montroig A, Fluxa G, Coll-Vinent B, Mont L, Naji F, Nedog V, Vokac D, Suran D, Kanic V, Granda S, Sabovic M. Poster Session 1: Atrial fibrillation clinical aspects. Europace 2009. [DOI: 10.1093/europace/euq214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
209
|
Matsuo K, Eno ML, Abouzied AM, Im DD, Rosenshein NB. Different expression of progesterone receptor between uterine serous carcinoma and ovarian serous carcinoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5578 Background: Clinical presentation and progression of uterine serous carcinoma (USC) often mimicks that of ovarian serous carcinoma (OSC), making the diagnosis difficult. The aim of this study is to compare characteristics of biomarker expression of USC to OSC. Methods: We evaluated all patients with FIGO stage III-IV USC and OSC, who underwent initial cytoreductive surgery between January 1, 1995, and March 31, 2008. Cases that received neoadjuvant chemotherapy were excluded. Patient demographics and clinico-pathologic data were abstracted from the medical records. Biomarker expression results were evaluated for mutation of p53 (m-p53), DNA profiling, multi-drug resistance gene-1 (MDR-1), estrogen receptor, and progesterone receptor. In-vitro drug resistance assay results were compared among platinum, taxane, cyclophosphamide, doxil, etoposide, gemcitabin, and topotecan (EDR Assay, Oncotech, Inc.). Results: There were 19 cases of USC and 185 cases of OSC identified. USC and OSC showed similar biomarker expressions except for the DNA index and expression of progesterone receptor. Biomarker expressions were: m-p53, 83.3% vs 68.7%, p = 0.28; DNA aneuploidity, 88.8% vs 80.8%, p = 0.53; DNA index, 1.7 (1.0–2.7) vs 1.5 (0.8–3.2), p = 0.044; S-phase fraction, 8.1% (3.1–19) vs 8.6% (0.3–19.2), p = 0.5; MDR-1, 33.3% vs 19.1%, p = 0.21; and estrogen receptor, 82.3% vs 82.9%, p = 1.0. Increased progesterone receptor expression was seen in USC compared to OSC (29.4% vs 9.2%, odds ratio 4.1, 95%CI 1.25–13.7, p = 0.028). In the in-vitro drug resistance assay, proportions of extreme drug resistance were similar in all tested drugs, including: cisplatin, 7.7% vs 7.2%, p = 0.5; carboplatin, 11.1% vs 9.5%, p = 0.3; paclitaxel 26.7% vs 23.5%, p = 1.0; doxil, 44.4% vs 33.9%, p = 0.69; and topotecan, 15.4% vs 18.5%, p = 1.0. Conclusions: Advanced uterine serous carcinoma was associated with increased expression of progesterone receptor compared to advanced ovarian serous carcinoma. The different expression potentially could be used to differentiate the two conditions and as a target in treatment therapies for uterine serous carcinoma. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Matsuo
- University of Maryland School of Medicine, Baltimore, MD; Mercy Medical Center, Baltimore, MD
| | - M. L. Eno
- University of Maryland School of Medicine, Baltimore, MD; Mercy Medical Center, Baltimore, MD
| | - A. M. Abouzied
- University of Maryland School of Medicine, Baltimore, MD; Mercy Medical Center, Baltimore, MD
| | - D. D. Im
- University of Maryland School of Medicine, Baltimore, MD; Mercy Medical Center, Baltimore, MD
| | - N. B. Rosenshein
- University of Maryland School of Medicine, Baltimore, MD; Mercy Medical Center, Baltimore, MD
| |
Collapse
|
210
|
Segawa Y, Hotta K, Takigawa N, Matsuo K, Yoshioka H, Hayashi H, Nogami N, Tabata M, Kiura K, Tanimoto M. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in pts with NSCLC previously treated with platinum-based chemotherapy: Results of Okayama Lung Cancer Study Group (OLCSG) trial 0503. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8058 Background: Recent studies have demonstrated that docetaxel (DOC) monotherapy provides a significant survival prolongation in relapsed pts with NSCLC. However, its benefit remains modest and further improvement is needed. S-1 is a newly developed oral 5-fluorouracil derivative, possessing a promising anti-tumor activity in NSCLC. Based on a superior effect of combination of DOC and 5-fluorouracil derivative (capecitabine) to DOC alone in anthracycline-pretreated breast cancer pts, we conducted a randomized phase II study to evaluate the clinical significance of adding S-1 to DOC in the second-line setting. Methods: Pts with relapsed NSCLC to the first-line platinum-based chemotherapy were randomly allocated to DOC monotherapy (A arm; 60 mg/m2, day 1, q 3 wks) or a combination chemotherapy (B arm) of DOC (40 mg/m2, day 1, q 3 wks) and S-1 (80 mg/m2, days 1 to 15). The doses of arm B were determined based on the results of a phase I study conducted for Japanese pts with gastric cancer (Anticancer Res 24: 1843, 2004). The primary endpoint was response rate and secondary endpoints included OS, PFS and toxicity. Results: Between 2005 and 2008, 60 pts were enrolled (A/B: 29/31 pts). Demographics of the pts were as follows: M/F: 49/11, Ad/others: 40/20, ECOG-PS 0/1: 38/22. A median number of courses administered was 4 (range: 1 to 6). Objective response was obtained in 6 (20.7%) and 5 pts (16.1%) in arms A and B, respectively. With a median follow-up time of 16.9 months, MST and median PFST in arm A were longer than arm B (22.9 vs. 8.7 months and 3.7 vs. 3.4 months, respectively). The major toxicity was myelosuppression, with grade 4 neutropenia of 62% vs. 29%, whereas thrombocytopenia was generally mild. Grade 3 febrile neutropenia was observed in 4 and 1 pts, none of whom further developed grade 5 toxicity. Other grade 3 or greater non-hematological adverse events included fever (B: 1 pt), pneumonitis (B: 1 pt), liver dysfunction (B: 2 pts), skin rash (B: 1 pt), and all of them were improved with an appropriate supportive care. Conclusions: The trial suggests that docetaxel monotherapy remains a standard therapy for NSCLC pts who relapsed to platinum-based chemotherapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Segawa
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| | - K. Hotta
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| | - N. Takigawa
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| | - K. Matsuo
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| | - H. Yoshioka
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| | - H. Hayashi
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| | - N. Nogami
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| | - M. Tabata
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| | - K. Kiura
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| | - M. Tanimoto
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| |
Collapse
|
211
|
Shitara K, Matsuo K, Takahari D, Yokota T, Ura T, Muro K. Neutropenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4115] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4115 Background: FOLFOX combined with bevacizumab is established as standard first-line chemotherapy for metastatic colorectal cancer (MCRC), and neutropenia is one of the most common of its side effects. Neutropenia during chemotherapy has been reported to be a predictor of better survival in patients with several type of cancers, although there are no reports in MCRC. We aimed to assess whether neutropenia during chemotherapy could be a marker of improved survival of patients with MCRC. Methods: Patients with MCRC who received FOLFOX with or without bevacizumab as first-line chemotherapy were retrospectively analyzed to assess whether neutropenia during chemotherapy is associated with improved survival. Several background characteristics and chemotherapy features (grade of neutropenia, use of bevacizumab, use of irinotecan, reintroduction of oxaliplatin, and tumor progression) as time-varying covariates (TVCs) were analyzed as potential prognostic factors. Results: Of 153 patients, mild neutropenia (grade 1–2) occurred in 60 patients (39%) and severe neutropenia (grade 3–4) occurred in 46 patients (30%). The other 47 patients (31%) did not experience neutropenia. In 106 patients experiencing neutropenia, 66% of patients experienced their highest grade within 4 cycles. According to a multivariate Cox model with TVCs, hazard ratios of death were 0.55 (95% CI, 0.31–0.98; P = 0.044) for patients with mild neutropenia and 0.35 (95% CI, 0.18–0.66; P = 0.002) for those with severe neutropenia. If the analysis of neutropenia was limited to 4 cycles of FOLFOX, mild or severe neutropenia remained a significant prognostic factor according to survival analysis with TVCs. Conclusions: Both mild and severe neutropenia during chemotherapy are associated with improved survival in patients with MCRC. Prospective trials are required to assess whether dosing adjustments based on neutropenia may improve chemotherapy efficacy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | | | | | | | - T. Ura
- Aichi Cancer Center, Nagoya, Japan
| | - K. Muro
- Aichi Cancer Center, Nagoya, Japan
| |
Collapse
|
212
|
Yoshino N, Kanekiyo M, Hagiwara Y, Okamura T, Someya K, Matsuo K, Ami Y, Sato S, Yamamoto N, Honda M. Mucosal Administration of Completely Non-Replicative Vaccinia Virus Recombinant Dairen I strain Elicits Effective Mucosal and Systemic Immunity. Scand J Immunol 2008; 68:476-83. [DOI: 10.1111/j.1365-3083.2008.02168.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
213
|
Suzuki T, Matsuo K, Sawaki A, Mizuno N, Hiraki A, Kawase T, Watanabe M, Nakamura T, Yamao K, Tajima K, Tanaka H. Alcohol Drinking and One-Carbon Metabolism-Related Gene Polymorphisms on Pancreatic Cancer Risk. Cancer Epidemiol Biomarkers Prev 2008; 17:2742-7. [DOI: 10.1158/1055-9965.epi-08-0470] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
214
|
Kanda J, Mizumoto C, Kawabata H, Tsuchida H, Tomosugi N, Matsuo K, Uchiyama T. Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation. Haematologica 2008; 93:1550-4. [DOI: 10.3324/haematol.12399] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
215
|
Matsuo K, Uchida N, Kawakubo M, Iguchi H, Okamura S, Matsuoka K, Akiyama T. Development of a phase contrast imaging system based on a yttrium aluminum garnet laser with folded beam for observations of density fluctuations in compact helical system. Rev Sci Instrum 2008; 79:10F514. [PMID: 19044659 DOI: 10.1063/1.2953574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
A near-infrared laser phase contrast optical system incorporating a folded beam was developed in order to measure the distribution of density fluctuations in a high-temperature plasma. The coherent light source used was an yttrium aluminum garnet laser stabilized by a ring oscillator. The probe beam system separates and reflects the incident and exiting beams with a polarizer and a fully reflective mirror with a waveplate. This system was employed with a compact helical system to detect fluctuations at the plasma edge.
Collapse
Affiliation(s)
- K Matsuo
- Fukuoka Institute of Technology, 3-30-1 Wajirohigashi Higashi-ku, Fukuoka-shi, Fukuoka 811-0295, Japan
| | | | | | | | | | | | | |
Collapse
|
216
|
Langevin SM, Lin D, Matsuo K, Gao CM, Takezaki T, Stolzenberg-Solomon RZ, Vasavi M, Hasan Q, Taioli E. Review and pooled analysis of studies on MTHFR C677T polymorphism and esophageal cancer. Toxicol Lett 2008; 184:73-80. [PMID: 18840514 DOI: 10.1016/j.toxlet.2008.09.003] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2008] [Revised: 09/03/2008] [Accepted: 09/03/2008] [Indexed: 12/23/2022]
Abstract
Esophageal cancer has been associated with tobacco and alcohol consumption, gastric reflux, exposure to nitrosamines from food or other environmental sources, and diets lacking folate. Susceptibility to esophageal cancer may be modified by functional polymorphisms in genes along the folate metabolic pathway, such as methylenetetrahydrofolate reductase (MTHFR). The C677T polymorphism is the most common functional variant, leading to a reduction in enzyme activity. We report a pooled analysis of 5 studies on the association of MTHFR C677T polymorphism and esophageal cancer, including 725 cases and 1531 controls. A significant association between the MTHFR 677 TT genotype and esophageal cancer was observed (OR=2.63, 95% CI: 1.75-3.94), although there was significant heterogeneity between studies. A sensitivity analysis excluded one study; the association between TT genotype and esophageal cancer was still present, although of reduced magnitude (OR=1.57, 95% CI: 0.96-2.56). A significant interaction between smoking and TT genotype on esophageal cancer risk was observed, while no interaction was observed between alcohol consumption and genotype.
Collapse
Affiliation(s)
- S M Langevin
- Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
217
|
Fu K, Tsujinaka Y, Hamahata Y, Matsuo K, Tsutsumi O. Squamous metaplasia of the rectum associated with ulcerative colitis diagnosed using narrow-band imaging. Endoscopy 2008; 40 Suppl 2:E45-6. [PMID: 18300203 DOI: 10.1055/s-2007-966861] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- K Fu
- Department of Coloproctology, Tokatsu-Tsujinaka Hospital, Chiba, Japan.
| | | | | | | | | |
Collapse
|
218
|
Fu K, Tsujinaka Y, Hamahata Y, Matsuo K, Tsutsumi O. "A brownish depressed area": a novel narrow band imaging colonoscopic finding of a depressed adenoma. Gut 2008; 57:1177; author reply 1177-8. [PMID: 18628380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/08/2022]
|
219
|
Ban R, Shinohara H, Matsuo K, Tanaka Y, Ikegami M. Limited distribution of gravitation abscess caused by infected preauricular sinus depends on anatomical structure. Eur J Plast Surg 2008. [DOI: 10.1007/s00238-008-0241-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
220
|
|
221
|
Kiura K, Takigawa N, Segawa Y, Kamei H, Takemoto M, Tabata M, Ueoka H, Hiraki S, Matsuo K, Tanimoto M. Randomized phase III trial of docetaxel and cisplatin combination chemotherapy versus mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.7515] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
222
|
Goto M, Yoshikawa Y, Matsuo K, Shirasu A, Ogawa N, Takahashi H, Saitoh Y, Goto M, Fujimori K, Kurokawa Y, Tamai M, Satomi S. Optimization of a prominent oxygen-permeable device for pancreatic islets. Transplant Proc 2008; 40:411-2. [PMID: 18374084 DOI: 10.1016/j.transproceed.2008.01.056] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
BACKGROUND We have demonstrated a culture bag system that is useful for pancreatic islet transplantation. To improve and simplify islet transplantation procedures from culture to transplantation, we developed a novel device specific for both islet culture and transplantation (TUBERO Device [TD]) using an oxygen-permeable material. MATERIALS AND METHODS Porcine islets with 30 minutes warm ischemia time were cultured for 24 hours at 37 degrees C in 5% CO2 and humidified air under three different procedures: (1) ordinary culture flask, (2) culture bag suitable for platelets, and (3) TD. Loss of islets during culture, glucose-stimulated insulin release as an islet functional test, and ADP/ATP ratio as an index of islet viability tests were evaluated to compare the devices. TD was further applied in two clinical islet transplantations using non-heart-beating donors in Japan. RESULTS The loss of islets during culture was considerably lower in the TD group. The stimulation index upon glucose challenge tests was significantly higher in the TD group than the others. The ADP/ATP ratio in TD group was significantly lower than that in the ordinary flask group, suggesting that the apoptotic islets were relatively lower among TD. Most importantly, TD was successfully applied both in the clinical islet cultures and in transplantation, resulting in excellent graft function. CONCLUSIONS We propose that the TD, a novel product, not only simplifies islet transplantation procedures, but also maintain the quality of isolated islets.
Collapse
Affiliation(s)
- M Goto
- Tohoku University Biomedical Engineering Research Organization, Tohoku University, Sendai, Japan; Division of Advanced Surgical Science and Technology, Tohoku University, Sendai, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
223
|
Sugimoto K, Narimatsu H, Kawase T, Iida H, Watanabe M, Kohno A, Kuwatsuka Y, Uchida T, Hamaguchi M, Terakura S, Naoe T, Matsuo K, Murata M, Sawa M, Miyamura K, Morishita Y. Clinical characteristics of chronic graft-versus-host disease following umbilical cord blood transplantation for adults. Bone Marrow Transplant 2008; 41:729-36. [PMID: 18176617 DOI: 10.1038/sj.bmt.1705959] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Chronic GVHD is a significant complication following allogeneic hematopoietic stem cell transplantation; however, the clinical characteristics of chronic GVHD following cord blood transplantation (CBT) in adults have not been well described. Between March 2001 and November 2005, a total of 77 patients underwent CBT at eight transplantation centers of the Nagoya Blood and Marrow Transplantation Group. Of 77 patients, 29 survived without graft failure or progression of underlying diseases for at least 100 days after transplantation. The median age of the 29 patients was 42 years (range, 18-67 years). Seven patients developed chronic GVHD (extensive, n=4; limited, n=3) disease. The cumulative incidence of chronic GVHD 1 year after day 100 was 24% (95% confidence interval (CI), 11-41%), and the organs involved were the skin (n=6), oral cavity (n=4), liver (n=1) and gastrointestinal tract (n=1). In three patients, chronic GVHD was resolved with supportive care. The remaining four were successfully treated with additional immunosuppressive therapy. Event-free survival rates of the 29 patients with and without chronic GVHD 3 years after day 100 were 83 (95% CI, 27-97%) and 36% (95% CI, 17-56%), respectively (P=0.047). These results suggest that chronic GVHD following CBT is mild and has a graft-versus-malignancy effect.
Collapse
Affiliation(s)
- K Sugimoto
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
224
|
Niibe Y, Tsunoda S, Jobo T, Imai M, Matsuo K, Matsunaga K, Unno N, Hayakawa K. Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma (LAUCC): Kitasato Gynecologic Radiation Oncology Group (KGROG 0501)--initial analysis. EUR J GYNAECOL ONCOL 2008; 29:222-224. [PMID: 18592783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
OBJECTIVE Locally advanced uterine cervical carcinoma (LAUCC) treated with chemoradiotherapy is considered to be the standard treatment regimen. However, no evidence of its efficacy and safety has been obtained from the Japanese population. Furthermore, the total dose of Japanese radiation therapy protocol is less than that of the USA which indicated that chemoradiotherapy for LAUCC is better than radiation therapy alone by phase III clinical trials. Thus, the current phase II study was designed to evaluate chemoradiotherapy with a lower radiation dose for LAUCC using weekly nedaplatin effectively and safely in the Japanese population. Nedaplatin is a platinum drug and no hydration is required to infuse patients because it is less toxic on renal function. If this phase II trial is successful, chemoradiotherapy for LAUCC in out-patient clinics could be possible. PATIENTS AND METHODS Patients registered in the current study were found to have LAUCC based on the following criteria i) pathologically proven squamous cell carcinoma or adenocarcinoma, ii) FIGO clinical Stage Ib, IIa, IIb with bulky tumor (diameter > 40 mm assessed by pelvic magnetic resonance imaging) or pelvic lymph node swelling (diameter > 10 mm assessed by pelvic computed tomography); iii) FIGO clinical Stage IIIa, IIIb and IVa with no paraaortic lymph node swelling (diameter > 10 mm) observed by abdominal computed tomography; iv) age: 20-75 years; v) performance status: 0-2. The treatment protocol was as follows: Radiation therapy in a combination of external beam radiation therapy (total dose: 50 Gy-52 Gy/25-27 fractions with central shielding after 30-32 Gy) with high-dose rate intracavitary irradiation (24-30 Gy/4-6 fractions to point A). Chemotherapy applied in the current study was weekly nedaplatin infused intravenously (30 mg/mm2/time, once a week, total 150 mg/mm2/5 weeks). Sample size in the current study was 45 LAUCC patients recruited for three years at a single institution. This protocol was permitted by the ethics committee of Kitasato University Hospital. RESULTS Ten patients were registered in this study between June 2005 and March 2006. The median age was 57.5 years (range 36-73). PS0 was five and PS1 was five. As for clinical stage, nine were IIIb and only one was IIb. Nine patients were proven to have squamous cell carcinoma and one adenocarcinoma. The median maximum tumor diameter was 62.5 mm (range 30-100 mm). As for initial response, eight had CR and two had PR (100% response rate). As for hematological acute morbidity, three were grade 2, six were grade 3, and one was grade 4. CONCLUSIONS This initial analysis of the phase II study confirmed that concurrent chemoradiotherapy using nedaplatin is safe and efficacious, thus we decided to undergo further studies.
Collapse
Affiliation(s)
- Y Niibe
- Department of Radiology, Kitasato University School of Medicine, Sagamihara, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
225
|
Toyoshima A, Haba H, Tsukada K, Asai M, Akiyama K, Goto S, Ishii Y, Nishinaka I, Sato TK, Nagame Y, Sato W, Tani Y, Hasegawa H, Matsuo K, Saika D, Kitamoto Y, Shinohara A, Ito M, Saito J, Kudo H, Yokoyama A, Sakama M, Sueki K, Oura Y, Nakahara H, Schädel M, Brüchle W, Kratz JV. Hexafluoro complex of rutherfordium in mixed HF/HNO3 solutions. RADIOCHIM ACTA 2008. [DOI: 10.1524/ract.2008.1474] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
226
|
Takeda K, Morioka D, Matsuo K, Endo I, Sekido H, Moroboshi T, Togo S, Shimada H. A Case of Successful Resection After Long-term Medical Treatment of Invasive Pulmonary Aspergillosis Following Living Donor Liver Transplantation. Transplant Proc 2007; 39:3505-8. [DOI: 10.1016/j.transproceed.2007.05.085] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2006] [Revised: 04/17/2007] [Accepted: 05/22/2007] [Indexed: 11/28/2022]
|
227
|
Morioka D, Tanaka K, Takeda K, Matsuo K, Kimura J, Yahagi S, Endo I, Sekido H, Togo S, Shimada H. Delayed Bile Leakage From a Remaining Part of Segment 8 in a Posterior Section Graft After Living Donor Liver Transplantation: A Common Pitfall in Harvesting a Posterior Section Graft? A Case Report. Transplant Proc 2007; 39:3515-8. [DOI: 10.1016/j.transproceed.2007.07.082] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2006] [Revised: 03/27/2007] [Accepted: 07/21/2007] [Indexed: 10/22/2022]
|
228
|
Ninomiya M, Kondo K, Matsuo K, Hirabayashi N, Kojima H, Kobayashi M, Kawamura S, Ando T, Musha N, Konno H, Nagata N, Usuki H, Miyashita Y, Oba K, Morita S, Sakamoto J. Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma. J Chemother 2007; 19:444-50. [PMID: 17855190 DOI: 10.1179/joc.2007.19.4.444] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
The aim of this study was to investigate the efficacy and safety of combination chemotherapy with weekly paclitaxel and 5-fluorouracil (5-FU) as first-line treatment in patients with advanced or recurrent gastric carcinoma. A total of 65 patients were treated with the following regimen, administered every 28 days; 5-FU 600 mg/m2 by 24-hour continuous infusion from days 1 through 5, and weekly paclitaxel 80 mg/m2 by 3-hour intravenous infusion on days 8, 14, and 21. A total of 272 cycles were conducted with a median of 4 (2-13) cycles per case. Out of 57 patients with measurable disease by RECIST criteria, there were 2 complete responses (3.5%), 20 partial responses (35.1%) and 25 cases with stable disease (43.9%). The overall response rate was 38.6% (95%CI: 26.0-51.2%). The median survival time and 1-year survival rates were 329 days and 47.4%, respectively. Both hematologic and non-hematologic toxicities were well tolerated.
Collapse
Affiliation(s)
- M Ninomiya
- Department of Surgery, Hiroshima City Hospital, Hiroshima, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
229
|
Matsuo K, Komoto Y, Kimura T, Shimoya K. Is 38 weeks late enough for elective cesarean delivery? Int J Gynaecol Obstet 2007; 100:90-1. [PMID: 17720164 DOI: 10.1016/j.ijgo.2007.06.040] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2007] [Revised: 06/07/2007] [Accepted: 06/07/2007] [Indexed: 10/22/2022]
Affiliation(s)
- K Matsuo
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.
| | | | | | | |
Collapse
|
230
|
Tanaka Y, Matsuo K, Yuzuriha S, Shinohara H, Kikuchi N, Moriizumi T. A transverse ligament located anterosuperiorly in the lower orbital fat space restricts lower eyelid retraction in the Mongoloid eye. J Plast Reconstr Aesthet Surg 2007; 61:603-9. [PMID: 17656169 DOI: 10.1016/j.bjps.2007.06.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2006] [Accepted: 06/14/2007] [Indexed: 11/26/2022]
Abstract
We previously reported that a lower positioned transverse ligament, which was identified just above the fusional line between the orbital septum and the levator aponeurosis or anteroinferiorly in the upper orbital fat space, determines the lower position of the preaponeurotic fat, and restricts the upper eyelid retraction causing the external features that define the appearance of the Mongoloid eye. Because the narrow palpebral fissure of the Mongoloid eye is composed of the restricted upper eyelid and the restricted lower eyelid, we surmised that the ligamentous tissue, which is analogous to the lower positioned transverse ligament in the upper eyelid, might also exist in the lower eyelid.
Collapse
Affiliation(s)
- Y Tanaka
- Department of Plastic and Reconstructive Surgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan
| | | | | | | | | | | |
Collapse
|
231
|
Sawaki A, Takayama R, Mizuno N, Tajika M, Hoki N, Sayed ZE, Matsuo K, Nakagawa H, Nakamura Y, Yamao K. Serum REG4 protein in pancreatic cancer as a tumor marker: A prospective study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15063 Background: Pancreatic cancer (PC) shows the worst mortality rate in common malignancies, with 5-year survival rate of 4%. The only way to cure the disease is surgical resection of early stage PC. Establishment of a screening strategy to detect early stage PC is eagerly expected. REG4, a member of the regenerating islet-derived (REG) family, are secreted proteins that play a role in tissue regeneration and inflammation in digestive organs. We reported overexpression of REG4 in PC cells and serum, and preliminary data of the serum REG4 level of pancreatic disease patients including PC patients. We conducted a prospective study to evaluate the role of serum REG4 in PC. Methods: The series included 57 patients diagnosed pathologically as PC between November 2004 and December 2005. Serum REG4 was quantified by standard sandwich ELISA (Enzyme Linked Immunosorbent Assay) using original kit (MBL116: provided by Medical and Biological Laboratories Co., LTD, Japan) before treatment. The upper limit of the test was set at 3.52ng/ml and was based on studies of serum from 48 healthy control subjects. Results: With a specificity of 100%, the diagnostic sensitivity and accuracy were 63.2% and 80.0%, respectively. The ROC (receiver operating characteristic) analysis showed that area under the curve was 0.91. REG4 levels were a significant differences between PC and control (p<0.001), between each T stage and control (T1,T2, T3 or T4 v control), and between each TMN stage and control (stage 1, stage 2, stage 3 or stage 4 v control), but were not a statistical significance with T stage (T1 v T2 v T3 v T4), M stage (M0 v M1) or TNM stage (stage 1 v stage 2 v stage 3 v stage 4) in PC patients. The diagnostic sensitivity of carcinoembryonic antigen (CEA>5.0ng/ml) and carbohydrate antigen19–9 (CA19–9>50U/ml) was 56.5% and 68.4%, respectively. No significant correlation was demonstrated between REG4 and CA19–9 (coefficient of correlation [rs]=0.45). Conclusions: This study shows the potential of serum REG4 as a screening test for PC, especially for early PC. REG4 is considered to be a more useful marker in combination with CA19- 9. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Sawaki
- Aichi Cancer Center, Nagoya, Japan; Institute of Medical Science, University of Tokyo, Tokyo, Japan
| | - R. Takayama
- Aichi Cancer Center, Nagoya, Japan; Institute of Medical Science, University of Tokyo, Tokyo, Japan
| | - N. Mizuno
- Aichi Cancer Center, Nagoya, Japan; Institute of Medical Science, University of Tokyo, Tokyo, Japan
| | - M. Tajika
- Aichi Cancer Center, Nagoya, Japan; Institute of Medical Science, University of Tokyo, Tokyo, Japan
| | - N. Hoki
- Aichi Cancer Center, Nagoya, Japan; Institute of Medical Science, University of Tokyo, Tokyo, Japan
| | - Z. E. Sayed
- Aichi Cancer Center, Nagoya, Japan; Institute of Medical Science, University of Tokyo, Tokyo, Japan
| | - K. Matsuo
- Aichi Cancer Center, Nagoya, Japan; Institute of Medical Science, University of Tokyo, Tokyo, Japan
| | - H. Nakagawa
- Aichi Cancer Center, Nagoya, Japan; Institute of Medical Science, University of Tokyo, Tokyo, Japan
| | - Y. Nakamura
- Aichi Cancer Center, Nagoya, Japan; Institute of Medical Science, University of Tokyo, Tokyo, Japan
| | - K. Yamao
- Aichi Cancer Center, Nagoya, Japan; Institute of Medical Science, University of Tokyo, Tokyo, Japan
| |
Collapse
|
232
|
Asano N, Suzuki R, Matsuo K, Kagami Y, Ishida F, Tamaru JI, Jin GS, Sato Y, Shimoyama Y, Yoshino T, Morishima Y, Nakamura S. Cytotoxic molecule expression is predictive of prognosis in Hodgkin's-like anaplastic large cell lymphoma. Histopathology 2007; 50:705-15. [PMID: 17493234 DOI: 10.1111/j.1365-2559.2007.02674.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
AIMS The Revised European American Lymphoma classification uses the term Hodgkin's-like anaplastic large cell lymphoma (HD-like ALCL) for borderline cases with features of both anaplastic large cell lymphoma (ALCL) and classical Hodgkin's lymphoma (HL). The aim of this study was to clarify the association between cytotoxic molecule (CM) expression and clinical outcome in HD-like ALCL. METHODS AND RESULTS Subjects were 59 patients with HD-like ALCL, defined by nodal presentation without mediastinal bulky lesions, T- or null-cell phenotype, CD30+ anaplastic lymphoma kinase (ALK)- phenotype and by confluent sheets or nodules of large cells mimicking classic Hodgkin and Reed-Sternberg cells. We evaluated the presenting features and prognosis of subjects on categorization into two defined groups, namely CM (TIA1 and/or granzyme B)-positive (n = 21) and CM-negative (n = 38). The series consisted of 18 women and 41 men ranging from 16 to 88 years of age (median 59 years). The CM+ group had poorer disease-specific survival than the CM- group (P = 0.02) despite the absence of differences in other clinical characteristics. Multivariate analysis confirmed that CM expression was an independent prognostic factor, in contrast to phenotypic categorization (T-cell vs. null-cell group), which had no prognostic impact on disease-specific survival. CONCLUSION CM expression is predictive of prognosis in HD-like ALCL.
Collapse
Affiliation(s)
- N Asano
- Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
233
|
Tanaka K, Shimada H, Matsuo K, Ueda M, Endo I, Togo S. Remnant liver regeneration after two-stage hepatectomy for multiple bilobar colorectal metastases. Eur J Surg Oncol 2007; 33:329-35. [PMID: 17140759 DOI: 10.1016/j.ejso.2006.10.038] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2006] [Accepted: 10/24/2006] [Indexed: 02/08/2023] Open
Abstract
AIMS Two-stage hepatectomy for multiple, bilobar liver metastases from colorectal cancer aimed to minimize liver failure risk by performing the second resection after regeneration, but impact of this strategy on volume of the future liver remnant (FLR) remained to be demonstrated. We compared two-stage hepatectomy with one stage following portal vein embolization (PVE) for multiple, bilobar liver metastases from colorectal cancer as to effects on volume of the FLR. METHODS Forty-three patients undergoing major hepatectomy for multiple colorectal cancer metastases were divided retrospectively into patients undergoing hepatectomy following PVE (n=21) and those undergoing two-stage hepatectomy (n=22). Increases in FLR volume were compared. RESULTS While the increase in the volume FLR averaged approximately 70 mL (302.6 mL before PVE vs. 370.9 mL after PVE) and the increase in the ratio of FLR to total liver volume averaged approximately 7.5% (30.2% to 37.5%) following PVE, first-stage hepatectomy increased FLR volume by approximately 100mL (from 259.4 to 361.4), and the ratio, by 15% (26.9% to 41.6%). The FLR hypertrophy ratio relative to pre-procedure volume estimates in the two-stage group (50.2%) was twice that in the PVE group (25.3%). CONCLUSIONS Superiority of two-stage hepatectomy in hypertrophy of the FLR was confirmed.
Collapse
Affiliation(s)
- K Tanaka
- Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
| | | | | | | | | | | |
Collapse
|
234
|
Sato H, Matsuo K, Miwa H, Hirohata T, Kohno M, Mayanagi Y, Kato N, Takigawa T, Tsunoda T, Kobayashi E. Efficacy of carotid artery stenting. Interv Neuroradiol 2007; 13 Suppl 1:94-9. [PMID: 20566084 DOI: 10.1177/15910199070130s113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2006] [Accepted: 01/15/2007] [Indexed: 11/15/2022] Open
Abstract
SUMMARY Carotid Artery Stenting(CAS) was performed for 51 lesions in 46 patients for almost clinically symptomatic stenotic (> 70%)lesions of cervical carotid arteries. The lesions involved the contralateral occlusion cases in eight cases, the bilateral stenotic cases in six cases and the ipsilateral internal carotid artery stenotic cases in two cases. In all cases, endovascular technique was performed from a transfemoral approach under local anesthesia primarily. Under systemic heparinization, CAS was performed using a selfexpanding stent system. For the pre-stenting and post-stenting dilatation, percutaneous transluminal angioplasty (PTA) balloon catheters were used. The balloon was inflated up to the pressure of six to ten atoms for 20 to 30 seconds.After CAS, stenotic lesion dilated successfully in all cases (0-20% residual stenosis; mean, 5.5%) even if in the case of the contra-lateral occlusion cases, more than 90% severe stenotic cases, and the tortuous artery cases. The cerebral protection system was always used, mainly distal blocking balloon type. Only one symptomatic complication occurred after CAS. Follow-up ultrasonic carotid echogram was performed in 30 cases.No cases showed restenosis (more than 50% restenosis). Clinical follow up was performed in all cases for one to 41 months (mean, 15.2 months) and no clinical deterioration such as TIA or stroke occurred. CAS is technically feasible and can be performed with relatively low morbidity even if complicated stenotic cases. It may be useful, but the increase the number of patients and the long-term follow-up are necessary to evaluate the safety and usefulness of this method.
Collapse
Affiliation(s)
- H Sato
- Department of Neurosurgery, Tokyo Metropolitan Police Hospital, Japan -
| | | | | | | | | | | | | | | | | | | |
Collapse
|
235
|
Matsuo K, Glahn DC, Peluso MAM, Hatch JP, Monkul ES, Najt P, Sanches M, Zamarripa F, Li J, Lancaster JL, Fox PT, Gao JH, Soares JC. Prefrontal hyperactivation during working memory task in untreated individuals with major depressive disorder. Mol Psychiatry 2007; 12:158-66. [PMID: 16983390 DOI: 10.1038/sj.mp.4001894] [Citation(s) in RCA: 189] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
The prefrontal cortex, a part of the limbic-thalamic-cortical network, participates in regulation of mood, cognition and behavior and has been implicated in the pathophysiology of major depressive disorder (MDD). Many neuropsychological studies demonstrate impairment of working memory in patients with MDD. However, there are few functional neuroimaging studies of MDD patients during working memory processing, and most of the available ones included medicated patients or patients with both MDD and bipolar disorder. We used functional magnetic resonance imaging (fMRI) to measure prefrontal cortex function during working memory processing in untreated depressed patients with MDD. Fifteen untreated individuals with Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition recurrent MDD (mean age+/-s.d.=34.3+/-11.5 years) and 15 healthy comparison subjects (37.7+/-12.1 years) matched for age, sex and race were studied using a GE/Elscint 2T MR system. An echo-planar MRI sequence was used to acquire 24 axial slices. The n-back task (0-back, 1-back and 2-back) was used to elicit frontal cortex activation. Data were analyzed with a multiple regression analysis using the FSL-FEAT software. MDD patients showed significantly greater left dorsolateral cortex activation during the n-back task compared to the healthy controls (P<0.01), although task performance was similar in the two groups. Furthermore, the patients showed significant anterior cingulate cortex activation during the task, but the comparison subjects did not (P<0.01). This study provides in vivo imaging evidence of abnormal frontolimbic circuit function during working memory processing in individuals with MDD.
Collapse
Affiliation(s)
- K Matsuo
- MOOD-CNS Program, Department of Psychiatry, Division of Mood and Anxiety Disorders, University of Texas Health Science Center, San Antonio, TX 78229-3900, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
236
|
Abstract
Uterine leiomyosarcoma occurring spontaneously in a domestic golden hamster was examined histologically and immunohistochemically. The histological findings for this tumour were similar to those for leiomyosarcomas described in other species. Immunohistochemical examination demonstrated the positivity of neoplastic cells with alpha-smooth muscle actin and desmin. From the results mentioned above, the tumour of this case was revealed to be of smooth muscle origin. To our knowledge, this is the first report of a uterine leiomyosarcoma in domestic golden hamsters.
Collapse
Affiliation(s)
- H Kondo
- Laboratory of Veterinary Pathology, College of Bioresource Science, Nihon University, 1866 Kameino, Fujisawa, Kanagawa, Japan
| | | | | | | | | | | |
Collapse
|
237
|
Ooe K, Tashiro Y, Saika D, Kitamoto Y, Matsuo K, Takabe T, Kuribayashi T, Takahashi N, Yoshimura T, Sato W, Takahisa K, Shinohara A. Development of On-line Solvent Extraction System with Microchips for Heavy Element Chemistry. ACTA ACUST UNITED AC 2007. [DOI: 10.14494/jnrs2000.8.59] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
238
|
Narimatsu H, Ota Y, Kami M, Takeuchi K, Suzuki R, Matsuo K, Matsumura T, Yuji K, Kishi Y, Hamaki T, Sawada U, Miyata S, Sasaki T, Tobinai K, Kawabata M, Atsuta Y, Tanaka Y, Ueda R, Nakamura S. Clinicopathological features of pyothorax-associated lymphoma; a retrospective survey involving 98 patients. Ann Oncol 2007; 18:122-128. [PMID: 17043091 DOI: 10.1093/annonc/mdl349] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
To investigate clinicopathological features of pyothorax-associated lymphoma (PAL), we examined medical records of 98 patients (88 males and 10 females) with PAL at a median age of 70 years (range 51-86). Seventy-nine patients had a history of artificial pneumothorax. Median interval between diagnosis and artificial pneumothorax was 43 years (range 19-64). At diagnosis, performance status (PS) was 0-1 (n=56) and 2-4 (n=42). Clinical stages were I (n=42), II (n=26), III (n=8) and IV (n=22). Pathological diagnosis comprised diffuse large-B-cell (n=78) and peripheral T-cell lymphoma (n=1). Seventeen were treated supportively. The other 81 received aggressive treatments; chemotherapy (n=52), radiotherapy (n=7), surgery (n=4) and combination (n=18). Five-year overall survival (OS) was 0.35 (95% confidence interval, 24% to 45%). Causes of deaths were PAL (n=39), respiratory failure (n=13) and others (n=12). Multivariate analysis identified prognostic factors for OS; lactate dehydrogenase levels [hazard ratio (HR)=2.36; P=0.013], sex (female versus male) (HR=0.15; P=0.01), PS (2-4 versus 0-1) (HR=2.20; P=0.02), clinical stages (III/IV versus I/II) (HR=1.95; P=0.037) and chemotherapy (HR=0.31; P=0.01). Most patients with PAL are elderly and have comorbidities, while some of them achieve durable remission with appropriate treatments. These findings prompt us to establish an optimal treatment strategy on the basis of risk stratification of individual patients.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Combined Modality Therapy
- Empyema, Pleural/epidemiology
- Empyema, Pleural/pathology
- Female
- Humans
- Lymphoma, B-Cell/pathology
- Lymphoma, B-Cell/therapy
- Lymphoma, Large B-Cell, Diffuse/pathology
- Lymphoma, Large B-Cell, Diffuse/therapy
- Lymphoma, T-Cell/pathology
- Lymphoma, T-Cell/therapy
- Male
- Middle Aged
- Pneumothorax, Artificial
- Prognosis
- Retrospective Studies
- Survival Rate
- Treatment Outcome
Collapse
Affiliation(s)
- H Narimatsu
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya
| | - Y Ota
- Department of Pathology, Toranomon Hospital, Tokyo
| | - M Kami
- Division of Exploratory Research, the Institute of Medical Science, the University of Tokyo, Tokyo.
| | - K Takeuchi
- Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - R Suzuki
- Division of Molecular Medicine, Aichi Cancer Center, Nagoya
| | - K Matsuo
- Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya
| | - T Matsumura
- Division of Exploratory Research, the Institute of Medical Science, the University of Tokyo, Tokyo
| | - K Yuji
- Division of Exploratory Research, the Institute of Medical Science, the University of Tokyo, Tokyo
| | - Y Kishi
- Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Tochigi
| | - T Hamaki
- Department of Transfusion Medicine, Metropolitan Fuchu Hospital, Tokyo
| | - U Sawada
- First Department of Internal Medicine, Nihon University School of Medicine, Tokyo
| | - S Miyata
- Department of Radiology, Toyama Prefectural Central Hospital, Toyama
| | - T Sasaki
- Department of Chemotherapy, Tokyo Metropolitan Komagome Hospital, Tokyo
| | - K Tobinai
- Hematology Division, National Cancer Center Hospital, Tokyo
| | - M Kawabata
- Division of Respiratory Diseases, Toranomon Hospital, Tokyo
| | - Y Atsuta
- Division of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya
| | - Y Tanaka
- Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Tokyo
| | - R Ueda
- Department of Internal Medicine and Molecular Science, Nagoya City University School of Medicine, Nagoya
| | - S Nakamura
- Department of Clinical Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
239
|
Matsuo K, Ushioda N, Harman CR, Kimura T. Increased leukocyte distribution in the pre‐clinical stage of pre‐eclampsia. Int J Gynaecol Obstet 2006; 96:31-2. [PMID: 17187797 DOI: 10.1016/j.ijgo.2006.09.020] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2006] [Revised: 09/18/2006] [Accepted: 09/19/2006] [Indexed: 10/23/2022]
Affiliation(s)
- K Matsuo
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.
| | | | | | | |
Collapse
|
240
|
Narimatsu H, Terakura S, Matsuo K, Oba T, Uchida T, Iida H, Hamaguchi M, Watanabe M, Kohno A, Murata M, Sawa M, Miyamura K, Morishita Y. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults. Bone Marrow Transplant 2006; 39:31-9. [PMID: 17115066 DOI: 10.1038/sj.bmt.1705539] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Post transplant immune disorders are problematic in cord blood transplantation (CBT) for adult patients, and optimal prophylaxis has not been established. We investigated whether intensive graft-versus-host disease (GVHD) prophylaxis using short-term methotrexate (MTX) has a prognostic impact on CBT. Post-CBT immune reactions were classified according to time course as pre-engraftment immune reaction (PIR), engraftment syndrome (ES) or acute GVHD. Between March 2001 and November 2005, a total of 77 patients underwent CBT at eight transplantation centers. Median age was 48 years (range, 18-69 years). Preparative regimens comprised myeloablative (n=31) or reduced-intensity (n=46). Acute GVHD prophylaxis included cyclosporine alone (n=23), tacrolimus alone (n=12), cyclosporine plus MTX (n=17), tacrolimus plus short-term MTX (n=23) or cyclosporine plus methylprednisolone (n=2). Cumulative incidences of PIR, ES and grade II-IV GVHD were 36, 12 and 23%, respectively. Short-term MTX exerted significant favorable effects on post-CBT immune reactions (hazard ratio, 0.55; 95% confidence interval (95% CI), 0.31-0.98; P=0.04) in multivariate analysis. Overall survival rates for patients with and without short-term MTX at day 180 were 59% (95% CI, 42-73%) and 16% (95% CI, 6.6-30%) (P=0.0001), respectively. Short-term MTX could offer one optimal regimen to reduce immune reactions and improve outcomes in CBT.
Collapse
Affiliation(s)
- H Narimatsu
- Department of Hematology, Toyohashi Municipal Hospital, Toyohashi, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
241
|
Takigawa N, Kiura K, Segawa Y, Watanabe Y, Kamei H, Moritaka T, Shibayama T, Ueoka H, Gemba K, Yonei T, Tabata M, Shinkai T, Hiraki S, Takemoto M, Kanazawa S, Matsuo K, Tanimoto M. Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer. Br J Cancer 2006; 95:1142-4. [PMID: 17031394 PMCID: PMC2360581 DOI: 10.1038/sj.bjc.6603422] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Long-term cancer survivors risk development of second primary cancers (SPC). Vigilant follow-up may be required. We report outcomes of 92 patients who underwent chemoradiation for unresectable stage III non-small-cell lung cancer, with a median follow-up of 8.9 years. The incidence of SPC was 2.4 per 100 patient-years (95% confidence interval: 1.0–4.9).
Collapse
Affiliation(s)
- N Takigawa
- Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
242
|
Suzuki T, Matsuo K, Sawaki A, Ito H, Hirose K, Wakai K, Sato S, Nakamura T, Yamao K, Ueda R, Tajima K. Systematic review and meta-analysis: importance of CagA status for successful eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 24:273-80. [PMID: 16842453 DOI: 10.1111/j.1365-2036.2006.02994.x] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
BACKGROUND Some, but not all studies have provided evidence that the CagA status of Helicobacter pylori strains is a predictive factor for the outcome of eradication therapy. AIM To clarify the association between CagA status and eradication outcome. METHODS We included studies reporting the numbers of successful and failed cases in H. pylori-eradication therapy according to the CagA status. Fourteen studies (1529 patients) were included of 325 articles identified in the search. The pooled risk ratio for H. pylori-eradication failure in CagA-negative relative to CagA-positive strains and the pooled risk difference in eradication success between the two groups were used as summary statistics. Meta-regression was used for examining the source of heterogeneity. RESULTS The summary risk ratio for eradication failure in CagA-negative relative to CagA-positive was 2.0 (95% CI: 1.6-2.4, P < 0.001), corresponding with the summary risk difference for eradication success between the groups of 11% (95% CI: 3-19%, P = 0.011). Meta-regression analysis demonstrated that usage of polymerase chain reaction examination for CagA status and a high proportion of non-ulcer dyspepsia patients were factors for heterogeneity among studies. CONCLUSIONS Our meta-analysis confirmed the importance of the presence of CagA as a predictor for successful eradication of H. pylori.
Collapse
Affiliation(s)
- T Suzuki
- Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
243
|
Kiura K, Segawa Y, Tabata M, Takigawa N, Kamei H, Harita S, Ueoka H, Hiraki S, Matsuo K, Tanimoto M. Randomized phase III trial of docetaxel and cisplatin combination chemotherapy versus mitomycin, vindesine and cisplatin combination chemotherapy with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer: Preliminary report. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7101] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7101 Background: Standard treatment of locally advanced non-small cell lung cancer (NSCLC) is cisplatin-based chemotherapy with concurrent thoracic radiation therapy (TRT). Furuse et al. demonstrated a superiority of mitomycin, vindesine and cisplatin (MVP) chemotherapy with concurrent TRT over that with sequential TRT (JCO 17, 1999). We demonstrated that docetaxel plus cisplatin (DP) chemotherapy with concurrent TRT shows better response rate and survival (Kiura K et al. BJC 89, 2003). We conducted a randomized phase III trial that compared DP with MVP in locally advanced NSCLC patients when concurrently administered with TRT. Methods: We randomly assigned patients with good performance status (PS)-stage IIIA/IIIB NSCLC to receive DP or MVP chemotherapy. Chemotherapy consisted of docetaxel 40 mg/m2 and cisplatin 40 mg/m2 on days 1, 8, 29, & 36 in the DP arm and mitomycin 8 mg/m2 on days 1 & 29, vindesine 3 mg/m2 on days 1, 8, 29, & 36, and cisplatin 80 mg/m2 on days 1 & 29 in the MVP arm. In the both groups, TRT began on day 1 at a dose of 60 Gy (2 Gy per fraction and 5 fractions per week for a total of 30 fractions). Results: Two hundred patients entered the trial between July 2000 and July 2005. Pretreatment characteristics were well balanced between the two treatment arms as follows: male/female 92/7, 88/13; median age (range) 65 (40–75), 64 (34–75); stage IIIA/IIIB 33/66, 33/68; and PS of 0/1 46/53, 50/51, for the DP arm and for the MVP arm, respectively. The response rates for the DP arm and the MVP arm were 78.8% and 70.3%, respectively. The 1- and 2-year survival rates were 81.8% and 59.9% for the DP arm, and were 68.8% and 49.1% for the MVP arm, respectively. Median follow up time is 1.4 years in January 2006. Complete analysis will be fixed in July 2007. Conclusions: The DP arm is exactly reproducing the response rate and survival of the phase II trial we have previously reported. The MVP arm seems to reveal better results than that we expected. Radiation dose and schedule might explain the difference because Furuse et al. splitted 56 Gy of TRT in the MVP arm whereas we did not split 60 Gy of TRT. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Kiura
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sanyo National Hospital, Ube, Japan; Okayama Red Cross General Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Okayama University Graduate School, Okayama, Japan
| | - Y. Segawa
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sanyo National Hospital, Ube, Japan; Okayama Red Cross General Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Okayama University Graduate School, Okayama, Japan
| | - M. Tabata
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sanyo National Hospital, Ube, Japan; Okayama Red Cross General Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Okayama University Graduate School, Okayama, Japan
| | - N. Takigawa
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sanyo National Hospital, Ube, Japan; Okayama Red Cross General Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Okayama University Graduate School, Okayama, Japan
| | - H. Kamei
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sanyo National Hospital, Ube, Japan; Okayama Red Cross General Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Okayama University Graduate School, Okayama, Japan
| | - S. Harita
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sanyo National Hospital, Ube, Japan; Okayama Red Cross General Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Okayama University Graduate School, Okayama, Japan
| | - H. Ueoka
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sanyo National Hospital, Ube, Japan; Okayama Red Cross General Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Okayama University Graduate School, Okayama, Japan
| | - S. Hiraki
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sanyo National Hospital, Ube, Japan; Okayama Red Cross General Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Okayama University Graduate School, Okayama, Japan
| | - K. Matsuo
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sanyo National Hospital, Ube, Japan; Okayama Red Cross General Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Okayama University Graduate School, Okayama, Japan
| | - M. Tanimoto
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sanyo National Hospital, Ube, Japan; Okayama Red Cross General Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Okayama University Graduate School, Okayama, Japan
| |
Collapse
|
244
|
Fujiwara Y, Kiura K, Toyooka S, Hotta K, Tabata M, Takigawa N, Kozuki T, Ohashi K, Matsuo K, Tanimoto M. Never-smoking history predicts long-term survival in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.20047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
20047 Background: Factors affecting long-term survival after postoperative recurrence in non-small cell lung cancer (NSCLC) patients have not been fully understood. Furthermore, molecular features of them also have remained undetermined. The aim of this study was to identify these possible factors and to investigate their association with epidermal growth factor receptor (EGFR) mutation. Methods: Fifty-eight patients with postoperative recurrent NSCLC treated at Okayama University Hospital between January 1999 and December 2003 were retrospectively analyzed. We defined those surviving for 2 years or longer after postoperative recurrence as long-term survivors. Tumor samples for EGFR mutation analysis were available in 32 (55%) patients and were examined in exons 18 to 21 of EGFR using direct sequence method. Results: Demographics of 58 patients were as follows: median age 65 years (range, 33–85 years), male/female, 69%/31%; adenocarcinoma/others, 69%/31%; ever/never-smokers, 66%/34% and local/local and distant/distant recurrence; 29%/10%/61%. Median survival time and 1-year survival rate for 58 patients were 22.7 months and 79%, respectively, with a minimum follow-up time of 2 years. Half of 28 long-term survivors did not have any smoking history, whereas only 6 never-smokers were included in the remaining 30 patients who died within 2 years, indicating that never-smoking history is significantly associated with long-term survival (p=0.016). In multivariate analysis, never-smoking history was a significant predictive factor for long-term survival (Odds ratio 4.90, 95% confidence interval: 1.26–19.00, p=0.022). Among 32 patients analyzed for EGFR mutation, patients harboring EGFR mutation in ever-smokers and in never-smokers were 10% and 82%, respectively. Seven (47%) of 15 long-term survivors analyzed had EGFR mutation; however, only 4 (24%) of 17 patients who died within 2 years did (p = 0.169). Conclusions: Our data suggest that never-smoking history might have a favorable effect on long-term survival in postoperative recurrent NSCLC patients, and long-term survivors tend to have EGFR mutation. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Fujiwara
- Okayama University Graduate School, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - K. Kiura
- Okayama University Graduate School, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - S. Toyooka
- Okayama University Graduate School, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - K. Hotta
- Okayama University Graduate School, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - M. Tabata
- Okayama University Graduate School, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - N. Takigawa
- Okayama University Graduate School, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - T. Kozuki
- Okayama University Graduate School, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - K. Ohashi
- Okayama University Graduate School, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - K. Matsuo
- Okayama University Graduate School, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - M. Tanimoto
- Okayama University Graduate School, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan
| |
Collapse
|
245
|
Takigawa N, Segawa Y, Kiura K, Tabata M, Ueoka H, Yonei T, Shibayama T, Takata I, Matsuo K, Tanimoto M. Secondary primary cancer in the long-term survivors with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7147 Background: Although concurrent chemoradiotherapy (CT/RT) is associated with increased survival for patients (pts) with locally advanced non-small cell lung cancer (NSCLC), long-outcomes beyond 5 years have not been fully analyzed. Methods: Between 1994 and 1999, we conducted two phase II studies examining concurrent CT/RT for treatment of surgically unresectable stage IIIA or IIIB NSCLC. One regimen consisted of three cycles of 5-fluorouracil 500mg/m2 and cisplatin 20mg/m2, days 1–5, every 4 weeks and concurrent hyperfractionated thoracic RT (1.25Gy twice daily, total 62.5–70Gy) [FP-TRT] (Segawa et al. BJC 82, 2000). The other consisted of docetaxel 40mg/m2 and cisplatin 40mg/m2, days 1, 8, 29 and 36 and concurrent thoracic RT (2Gy daily, total 60Gy) [DP-TRT] (Kiura et al. BJC 89, 2003). Long-term data is presented. Results: In 50 pts treated with FP-TRT, the median survival time (MST) was 1.6 years (yr; 95% confidential interval [CI]: 0.91 - 2.25 yr) by a median follow-up time of 10.4 yr and the actual 5 yr-survival rate was 30%. In 15 long-term survivors, 3 and 2 pts died due to primary NSCLC and secondary primary cancer (SPC), respectively, 1 was lost to follow-up, and 9 are still alive. In 42 pts treated with DP-TRT, the MST was 2.1 yr (95% CI: 0.82 - 2.48 yr) by a median follow-up time of 6.3 yr and the actual 5 yr-survival rate was 31%. In 13 long-term survivors, 1 pt died due to primary NSCLC, 1 died due to SPC, 1 was lost to follow-up, and 10 are still alive. Overall, 7 of 92 pts enrolled in these studies developed SPCs (2 NSCLC, 1 small cell lung cancer, 2 esophageal cancers, 2 gall bladder cancers) although no pts developed leukemia or myelodysplastic syndrome. An observed incidence rate of SPCs was 2356.1/100,000 (95% CI: 947.6 - 4856.0). Cumulative incidence was 5.8% (standard error [SE] 4.0%) at 5 yr, 10.0% (SE 5.6%) at 8 yr and 60.8% (SE 18.9%) at 10 yr. The median time from the beginning of CT/RT to the diagnosis of SPC was 9.6 yr (95% CI: 8.1 - 11.1 yr). Conclusions: Approximately 30% of pts survived more than 5 years after concurrent CT/RT, however, they were still at risk of dying from primary NSCLC. Occurrence of SPC in long-term survivors should be concerned in follow-up. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. Takigawa
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - Y. Segawa
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - K. Kiura
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - M. Tabata
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - H. Ueoka
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - T. Yonei
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - T. Shibayama
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - I. Takata
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - K. Matsuo
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - M. Tanimoto
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| |
Collapse
|
246
|
Abstract
Spontaneously occurring cutaneous tumours in three golden hamsters were characterized using histological, immunohistochemical and ultrastructural methods. Histologically, the tumours were composed of sheets of round to oval plasmacytoid cells with eccentrically placed nuclei. Tissue sections were weakly positive for anti-B lymphocyte antigen (BLA) staining. Ultrastructurally, large amounts of rough endoplasmic reticulum in the cytoplasm were observed. BLA positivity and characteristics of ultrastructure showed the plasma cell origin.
Collapse
Affiliation(s)
- H Kondo
- Laboratory of Veterinary Pathology, College of Bioresource Science, Nihon University, 1866 Kameino, Fujisawa, Kanagawa 252-8510, Japan
| | | | | | | | | | | |
Collapse
|
247
|
Takano M, Iwadare J, Ohba H, Takamura H, Masuda Y, Matsuo K, Kanai T, Ieda H, Hattori Y, Kurata S, Koganezawa S, Hamano K, Tsuchiya S. Sclerosing therapy of internal hemorrhoids with a novel sclerosing agent. Comparison with ligation and excision. Int J Colorectal Dis 2006; 21:44-51. [PMID: 15843937 DOI: 10.1007/s00384-005-0771-0] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/15/2005] [Indexed: 02/04/2023]
Abstract
BACKGROUND AND AIMS Patients with prolapsing internal hemorrhoids were treated with a novel sclerosing agent (OC-108), and the results were compared with surgery of ligation and excision. PATIENTS AND METHODS This study included 20 years or older patients with prolapsing internal hemorrhoids who visited ten medical institutions in Japan from October 2000 to October 2002. Investigation on surgery was also performed. RESULTS Comparing OC-108 and surgery in patients with third- and fourth-degree internal hemorrhoids according to the Goligher's classification, for which surgery has been generally indicated, at 28 days after treatment, the disappearance rate of prolapse was similar between OC-108 and surgery, 94% (75/80 patients) and 99% (84/85 patients), respectively. The 1-year recurrence rate was 16% (12/73 patients) in the OC-108 group, and this value was satisfactory because of its less invasive nature while it was more or less higher compared with 2% (2/81 patients) in the surgery group. The incidences of pain and bleeding were lower in the OC-108 group. CONCLUSIONS OC-108 is a useful alternative treatment for hemorrhoids.
Collapse
Affiliation(s)
- M Takano
- Coloproctology Center, Takano Hospital, 4-2-88 Obiyama, Kumamoto 862-0924, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
248
|
Matsuo K, Kosaka K, Sugimoto T, Ikewaki K. Th-P15:17 Abnormal in vivo metabolism of apoB and VLDL TG associated with two sibling cases of sitosterolemia. ATHEROSCLEROSIS SUPP 2006. [DOI: 10.1016/s1567-5688(06)81977-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
249
|
Akada R, Matsuo K, Aritomi K, Nishizawa Y. Construction of recombinant sake yeast containing a dominant FAS2 mutation without extraneous sequences by a two-step gene replacement protocol. J Biosci Bioeng 2005; 87:43-8. [PMID: 16232423 DOI: 10.1016/s1389-1723(99)80006-1] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/1998] [Accepted: 10/06/1998] [Indexed: 11/24/2022]
Abstract
A novel two-step gene replacement protocol was developed to construct a recombinant industrial yeast free of bacterial and drug-resistant marker sequences. A yeast strain exhibiting cerulenin resistance conferred by a dominant mutation of FAS2 was previously shown to produce high levels of a flavor component of Japanese sake. A N- and C-terminally truncated portion of the mutant FAS2 gene was subcloned to an integrating plasmid containing an aureobasidin A-resistant transformation marker and a galactose-inducible growth inhibitory sequence (GAL10p::GIN11). The plasmid was targeted into the chromosomal FAS2 locus of sake yeast Kyokai no. 7, resulting in a tandem repeat of inactive FAS2 sequences surrounding the integrated plasmid sequences. Cells containing the integrated plasmid were unable to grow on galactose medium due to the inhibitory effect of GAL10p::GIN11. This growth inhibition allowed efficient counter-selection for cells that had undergone homologous recombination between the FAS2 repeats by their growth on galactose medium. This recombination event resulted in loss of the integrated plasmid sequences and the resulting strains should contain a single copy of either wild-type or cerulenin-resistant FAS2. The selected cerulenin-resistant strains produced approximately 3.7-fold more ethyl caproate, a flavor component, than the Kyokai no. 7 strain. Southern blot and sequence analyses confirmed the presence of the FAS2 mutation and the absence of integrated plasmid sequences in the genome of the selected strain. This gene replacement method provides a straightforward approach for the construction of recombinant industrial yeasts free of undesirable DNA sequences.
Collapse
Affiliation(s)
- R Akada
- Department of Applied Chemistry and Chemical Engineering, Faculty of Engineering, Yamaguchi University, Tokiwadai, Ube 755-8611 Japan
| | | | | | | |
Collapse
|
250
|
Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Harita S, Gemba K, Yonei T, Bessho A, Tanimoto M. Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Ann Oncol 2005; 16:1817-23. [PMID: 16157622 DOI: 10.1093/annonc/mdi369] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND This study aimed to investigate the survival outcome of patients with non-small-cell lung cancer (NSCLC) who had obtained disease stabilisation with gefitinib treatment and to clarify the effect of continued treatment with gefitinib on prognosis. PATIENTS AND METHODS We reviewed the clinical records of 365 Japanese patients with NSCLC who received gefitinib (250 mg/day). RESULTS Of 324 (89%) patients assessable for response, 147 (45%) obtained disease stabilisation and 71 (22%) patients achieved an objective response. Overall survival in patients obtaining disease stabilisation was significantly longer than in patients with progressive disease (median survival time 12.1 versus 4.4 months; P <0.0001). In patients obtaining disease stabilisation, those who continued gefitinib treatment until disease progression tended to have longer overall and progression-free survival compared with those discontinuing gefitinib treatment (1-year survival rate 52.1% versus 36.6%, P = 0.08; 1-year progression-free survival rate 31.8% versus 5.2%, P = 0.001). Multivariate analysis showed discontinuing gefitinib was an independent risk factor for progression-free survival (hazard ratio 1.66; 95% confidence interval 1.07-2.56; P = 0.022) but not for overall survival. CONCLUSIONS Our findings indicate the importance of achieving disease stabilisation with gefitinib treatment and continued gefitinib treatment in Japanese patients with disease stabilisation, although further studies are required to confirm these findings.
Collapse
Affiliation(s)
- K Hotta
- Department of Medicine II, Okayama University Medical School, Okayama.
| | | | | | | | | | | | | | | | | | | |
Collapse
|